These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36181110)
1. CIMP-positive glioma is associated with better prognosis: A systematic analysis. Xu Y; Xiao H; Hu W; Shen HC; Liu W; Tan S; Ren C; Zhang X; Yang X; Yu G; Yang T; Yu D; Zong L Medicine (Baltimore); 2022 Sep; 101(39):e30635. PubMed ID: 36181110 [TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of glioma identified by genome-wide methylation profiling. Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
5. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202 [TBL] [Abstract][Full Text] [Related]
6. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018 [TBL] [Abstract][Full Text] [Related]
7. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K; Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149 [TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622 [TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277 [TBL] [Abstract][Full Text] [Related]
12. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224 [TBL] [Abstract][Full Text] [Related]
13. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768 [TBL] [Abstract][Full Text] [Related]
14. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors. Schenkel LC; Mathew J; Hirte H; Provias J; Paré G; Chong M; Grafodatskaya D; McCready E Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360312 [TBL] [Abstract][Full Text] [Related]
16. Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Mur P; Mollejo M; Ruano Y; de Lope ÁR; Fiaño C; García JF; Castresana JS; Hernández-Laín A; Rey JA; Meléndez B Acta Neuropathol; 2013 Aug; 126(2):277-89. PubMed ID: 23689617 [TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
18. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791 [TBL] [Abstract][Full Text] [Related]
19. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093 [TBL] [Abstract][Full Text] [Related]
20. Treatment of anaplastic glioma. Wick W; Wiestler B; Platten M Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]